Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07473674 · ClinicalTrials.gov registry record · NA

Skin Prick Test to Evaluate Immunogenic Response of SILURCLOUD™ Fibrous Collagen Matrix in Healthy Volunteers

A NA study of Healthy Adult, sponsored by SerenaGroup.

Recruiting
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT07473674: Recruiting NA study of Healthy Adult, sponsored by SerenaGroup.

NCT07473674 is a NA study of Healthy Adult that is actively recruiting participants, run by SerenaGroup. The registered enrollment target is 8 participants, below the 73-participant average among 8 other Healthy Adult trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07473674, a NA study of Healthy Adult, is actively recruiting participants, sponsored by SerenaGroup.

RECRUITING
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate whether the SILURCLOUD™ Fibrous Collagen Matrix causes an allergic skin response in healthy adult volunteers. The main question it aims to answer is: Does the SILURCLOUD™ Fibrous Collagen Matrix produce a measurable allergic reaction following a skin prick test? Participants will: Undergo a skin prick test on the inner forearm using the study product and control substances Remain at the clinic for evaluation of the skin response approximately 15 minutes and 6 hours after application Return to the clinic 24-48 hours later for a final skin assessment The study will include healthy adult volunteers, including participants with Fitzpatrick Skin Type VI, to provide additional safety information requested by the U.S. FDA.

Primary Outcome

Allergic skin response will be assessed using a standardized skin prick test procedure. The reaction will be quantified by measuring the mean wheal diameter at the test site in millimeters (mm).

Conditions Studied

Interventions

  • DRUG Glycerosaline
  • DEVICE Collagen Matrix Skin Prick Test Device
  • DRUG Histamine

Study Locations (1)

Pennsylvania

  • SerenaGroup Monroeville - Monroeville

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2026-02
Est. Completion 2026-03
Phase NA
SerenaGroup

10 total trials

What NCT07473674 shows while recruiting

NCT07473674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 73-participant average among 8 other Healthy Adult trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Healthy Adult appearing as the primary indexed condition, and to 3 interventions - of which Glycerosaline is the first listed.

NCT07473674 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07473674 about?

NCT07473674 is a clinical study titled "Skin Prick Test to Evaluate Immunogenic Response of SILURCLOUD™ Fibrous Collagen Matrix in Healthy Volunteers". The goal of this clinical trial is to evaluate whether the SILURCLOUD™ Fibrous Collagen Matrix causes an allergic skin response in healthy adult volunteers. The main question it aims to answer is: Does the SILURCLOUD™ Fibrous Collagen Matrix produce a measurable allergic reaction following a skin p...

What is the current status of trial NCT07473674?

This trial is currently recruiting. It is a NA study. The enrollment target is 8 participants. The study started on 2026-02. Estimated completion is 2026-03.

What conditions does trial NCT07473674 study?

This clinical trial studies the following conditions: Healthy Adult.

What interventions are being tested in trial NCT07473674?

The interventions under investigation include: Glycerosaline (DRUG), Collagen Matrix Skin Prick Test Device (DEVICE), Histamine (DRUG).

Who is sponsoring clinical trial NCT07473674?

This trial is sponsored by SerenaGroup, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07473674 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07473674's enrollment target sits among peer trials

8 9th of 8 the lowest of 8 other Healthy Adult trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07473674, the US trial registry maintained by the National Library of Medicine. NCT07473674 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.